Industry, Patient Group Weigh in on FDA's Biosimilar Naming...

Industry, Patient Groups Weigh in on FDA's Biosimilar Naming ...

Regulatory Focus-7 hours ago

Industry is calling on the US Food and Drug Administration (FDA) to use to use "meaningful" and "distinguishable" suffixes linked to a biosimilar license holder's ...

USP Comments on FDA Draft Guidance on Nonproprietary Naming ...
PharmiWeb.com (press release)-9 hours ago

Explore in depth (3 more articles)